Biomedicine & Pharmacotherapy (Apr 2024)

Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis

  • Qiuyan Guo,
  • Minghong Zhao,
  • Qixin Wang,
  • Tianming Lu,
  • Piao Luo,
  • Lin Chen,
  • Fei Xia,
  • Huanhuan Pang,
  • Shengnan Shen,
  • Guangqing Cheng,
  • Chuanhao Dai,
  • Yuqing Meng,
  • Tianyu Zhong,
  • Chong Qiu,
  • Jigang Wang

Journal volume & issue
Vol. 173
p. 116304

Abstract

Read online

Glycyrrhetinic acid (GA) shows great efficiency against non-small cell lung cancer (NSCLC), but the detailed mechanism is unclear, which has limited its clinical application. Herein, we investigated the potential targets of GA against NSCLC by activity-based protein profiling (ABPP) technology and the combination of histopathology and proteomics validation. In vitro and in vivo results indicated GA significantly inhibited NSCLC via promotion of peroxiredoxin-6 (Prdx6) and caspase-3 (Casp3)-mediated mitochondrial apoptosis. This original finding will provide theoretical and data support to improve the treatment of NSCLC with the application of GA.

Keywords